Preclinical
EXUMA Biotech is developing a new modality to produce CAR cells in a single day, with potentially lower toxicity and higher efficacy without the need for preparative chemotherapies.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on Monday and recapped the laundry list of vaccines and treatments the company plans to develop.
Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than oncology.
BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
The platform, called LOCOcyte™, is a cytokine delivery platform that is made of polymer-encapsulated human ARPE-19 cells that produce natural cytokines.
The identification of multiple genomic markers that are linked to specific mental health diseases is beginning to improve treatments and enable precision psychiatry.
Akari announced that votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
PRESS RELEASES